HyaCare - Award winning innovation by Novozymes

Published: 9-Nov-2007
Ingredients Pharmaceutical

First Hyaluronic acid powder with enhanced surface properties


Novozymes HyaCare is the world's first Hyaluronic acid (HA) powder composed of fine particles with enhanced surface properties that improve solubilization time by three times than any other normal processes. It provides for good safety, purity, consistency, stability and ease of filtering.

Shift in paradigm

Novozymes is now radically shifting the paradigm of HA-production. By employing a unique and safe strain, Bacillus subtilis, as an 'industry factory' HyaCare is taking quality in terms of solubilisation, safety, purity, consistency, stability and ease of filtering to a level no one thought was possible just a few years back.

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com. Visit Novozymes Biopolymer at biopolymer.novozymes.com.

  • Companies:
  • Novozymes
See more

You may also like

Ingredients

Novozymes reports a good year in 2014

Read more
Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  4. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Diversity aids a biotech boom

The biotech sector is boosted by invention and shows no sign of slowing. Biopharmaceutical pipelines are broadening and production techniques improving. Susan Birks reports
Research & Development

Novozymes Biopharma enters agreement with leading vaccine company

To conduct research on a novel subunit vaccine complex based on albumin fusion technology
Research & Development

Novozymes Biopharma to offer drug-albumin conjugation platform with ThioLogics

New partnership to offer serum-stable drug-albumin conjugation capability
Manufacturing

GSK uses Novozymes\' Veltis half-life extension technology in once-weekly diabetes drug

Novozymes technology used in recently approved Eperzan type 2 diabetes treatment
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Finance

Novozymes reports 4% increase in sales in Q1

Biopharma sales rise by 22%
Subscribe now